Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Germline POT1 variants can predispose to myeloid and lymphoid neoplasms.
Lim TL, Lieberman DB, Davis AR, Loren AW, Hausler R, Bigdeli A, Li Y, Powers J, Raper A, Regeneron Genetics Center, Carty SA, Nathanson KL, Bagg A, Hexner EO, Maxwell KN, Morrissette JJD, Babushok DV. Lim TL, et al. Among authors: bagg a. Leukemia. 2022 Jan;36(1):283-287. doi: 10.1038/s41375-021-01335-w. Epub 2021 Jun 30. Leukemia. 2022. PMID: 34193977 Free PMC article. No abstract available.
Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene.
Tsai DE, Luger SM, Kemner A, Swider C, Goradia A, Tomczak E, DiPatri D, Bagg A, Nowell P, Loren AW, Perl A, Schuster S, Thompson JE, Porter D, Andreadis C, Stadtmauer EA, Goldsteini S, Ghalie R, Carroll M. Tsai DE, et al. Among authors: bagg a. Cancer Biol Ther. 2007 Jan;6(1):18-21. doi: 10.4161/cbt.6.1.3619. Cancer Biol Ther. 2007. PMID: 17204865
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.
Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Mato AR, Carroll M. Tsai DE, et al. Among authors: bagg a. Clin Cancer Res. 2008 Sep 1;14(17):5619-25. doi: 10.1158/1078-0432.CCR-07-5185. Clin Cancer Res. 2008. PMID: 18765556 Clinical Trial.
A robust xenotransplantation model for acute myeloid leukemia.
Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, Swider CR, Bagg A, Choi JK, Biegel JA, Danet-Desnoyers G, Carroll M. Sanchez PV, et al. Among authors: bagg a. Leukemia. 2009 Nov;23(11):2109-17. doi: 10.1038/leu.2009.143. Epub 2009 Jul 23. Leukemia. 2009. PMID: 19626050 Free PMC article.
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM. Perl AE, et al. Among authors: bagg a. Clin Cancer Res. 2009 Nov 1;15(21):6732-9. doi: 10.1158/1078-0432.CCR-09-0842. Epub 2009 Oct 20. Clin Cancer Res. 2009. PMID: 19843663 Clinical Trial.
250 results